Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin

Chansoo Moon, Kyu Sik Jung, Do Young Kim, Oidov Baatarkhuu, Jun Yong Park, Beom Kyung Kim, Seung Up Kim, Sang Hoon Ahn, Kwang Hyub Han

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: To elucidate the benefits of successful antiviral therapy in chronic hepatitis C (CHC) patients.

Results: Three hundred patients achieved SVR, and 163 were classified into the non-SVR group. The overall SVR rates were 64.8 %, and multivariate analysis showed that younger age, non-cirrhosis, HCV genotype 2 or 3, lower HCV RNA level (<800,000 IU/mL), and lower body weight were independent factors associated with SVR (all P < 0.05). During a median follow-up of 36.1 months, non-cirrhotic patients with SVR had significantly lower risk of progression to cirrhosis compared with patients with non-SVR (P < 0.001). Moreover, SVR was related to a reduced risk of HCC development (P = 0.017).

Methods: A total of 463 CHC patients who underwent pegylated interferon alfa and ribavirin therapy were classified as sustained virological response (SVR) or non-SVR based on response to antiviral therapy. We investigated disease progression to cirrhosis in non-cirrhotic patients, development of cirrhosis-related complications such as ascites, variceal bleeding, and hepatic encephalopathy in patients with cirrhosis, and development of hepatocellular carcinoma (HCC).

Conclusions: SVR resulted in significantly more favorable long-term outcomes, such as lower risk of progression to cirrhosis and HCC occurrence compared with non-SVR.

Original languageEnglish
Pages (from-to)573-581
Number of pages9
JournalDigestive diseases and sciences
Volume60
Issue number2
DOIs
Publication statusPublished - 2015 Jan 23

Fingerprint

Ribavirin
Hepatitis C
Interferons
Hepatocellular Carcinoma
Fibrosis
Incidence
Chronic Hepatitis C
Antiviral Agents
Hepatic Encephalopathy
Ascites
Interferon-alpha
Disease Progression
Therapeutics
Multivariate Analysis
Genotype
Body Weight
RNA
Hemorrhage

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

@article{5db20216192442889824c69b05539f53,
title = "Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin",
abstract = "Background: To elucidate the benefits of successful antiviral therapy in chronic hepatitis C (CHC) patients.Results: Three hundred patients achieved SVR, and 163 were classified into the non-SVR group. The overall SVR rates were 64.8 {\%}, and multivariate analysis showed that younger age, non-cirrhosis, HCV genotype 2 or 3, lower HCV RNA level (<800,000 IU/mL), and lower body weight were independent factors associated with SVR (all P < 0.05). During a median follow-up of 36.1 months, non-cirrhotic patients with SVR had significantly lower risk of progression to cirrhosis compared with patients with non-SVR (P < 0.001). Moreover, SVR was related to a reduced risk of HCC development (P = 0.017).Methods: A total of 463 CHC patients who underwent pegylated interferon alfa and ribavirin therapy were classified as sustained virological response (SVR) or non-SVR based on response to antiviral therapy. We investigated disease progression to cirrhosis in non-cirrhotic patients, development of cirrhosis-related complications such as ascites, variceal bleeding, and hepatic encephalopathy in patients with cirrhosis, and development of hepatocellular carcinoma (HCC).Conclusions: SVR resulted in significantly more favorable long-term outcomes, such as lower risk of progression to cirrhosis and HCC occurrence compared with non-SVR.",
author = "Chansoo Moon and Jung, {Kyu Sik} and Kim, {Do Young} and Oidov Baatarkhuu and Park, {Jun Yong} and Kim, {Beom Kyung} and Kim, {Seung Up} and Ahn, {Sang Hoon} and Han, {Kwang Hyub}",
year = "2015",
month = "1",
day = "23",
doi = "10.1007/s10620-014-3361-6",
language = "English",
volume = "60",
pages = "573--581",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin

AU - Moon, Chansoo

AU - Jung, Kyu Sik

AU - Kim, Do Young

AU - Baatarkhuu, Oidov

AU - Park, Jun Yong

AU - Kim, Beom Kyung

AU - Kim, Seung Up

AU - Ahn, Sang Hoon

AU - Han, Kwang Hyub

PY - 2015/1/23

Y1 - 2015/1/23

N2 - Background: To elucidate the benefits of successful antiviral therapy in chronic hepatitis C (CHC) patients.Results: Three hundred patients achieved SVR, and 163 were classified into the non-SVR group. The overall SVR rates were 64.8 %, and multivariate analysis showed that younger age, non-cirrhosis, HCV genotype 2 or 3, lower HCV RNA level (<800,000 IU/mL), and lower body weight were independent factors associated with SVR (all P < 0.05). During a median follow-up of 36.1 months, non-cirrhotic patients with SVR had significantly lower risk of progression to cirrhosis compared with patients with non-SVR (P < 0.001). Moreover, SVR was related to a reduced risk of HCC development (P = 0.017).Methods: A total of 463 CHC patients who underwent pegylated interferon alfa and ribavirin therapy were classified as sustained virological response (SVR) or non-SVR based on response to antiviral therapy. We investigated disease progression to cirrhosis in non-cirrhotic patients, development of cirrhosis-related complications such as ascites, variceal bleeding, and hepatic encephalopathy in patients with cirrhosis, and development of hepatocellular carcinoma (HCC).Conclusions: SVR resulted in significantly more favorable long-term outcomes, such as lower risk of progression to cirrhosis and HCC occurrence compared with non-SVR.

AB - Background: To elucidate the benefits of successful antiviral therapy in chronic hepatitis C (CHC) patients.Results: Three hundred patients achieved SVR, and 163 were classified into the non-SVR group. The overall SVR rates were 64.8 %, and multivariate analysis showed that younger age, non-cirrhosis, HCV genotype 2 or 3, lower HCV RNA level (<800,000 IU/mL), and lower body weight were independent factors associated with SVR (all P < 0.05). During a median follow-up of 36.1 months, non-cirrhotic patients with SVR had significantly lower risk of progression to cirrhosis compared with patients with non-SVR (P < 0.001). Moreover, SVR was related to a reduced risk of HCC development (P = 0.017).Methods: A total of 463 CHC patients who underwent pegylated interferon alfa and ribavirin therapy were classified as sustained virological response (SVR) or non-SVR based on response to antiviral therapy. We investigated disease progression to cirrhosis in non-cirrhotic patients, development of cirrhosis-related complications such as ascites, variceal bleeding, and hepatic encephalopathy in patients with cirrhosis, and development of hepatocellular carcinoma (HCC).Conclusions: SVR resulted in significantly more favorable long-term outcomes, such as lower risk of progression to cirrhosis and HCC occurrence compared with non-SVR.

UR - http://www.scopus.com/inward/record.url?scp=84922072786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922072786&partnerID=8YFLogxK

U2 - 10.1007/s10620-014-3361-6

DO - 10.1007/s10620-014-3361-6

M3 - Article

C2 - 25236421

AN - SCOPUS:84922072786

VL - 60

SP - 573

EP - 581

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 2

ER -